



THE LATEST INNOVATION IN THE CONTINUUM OF CARE FOR DPN

The WaveWriter Alpha™ SCS System is now FDA approved
for Diabetic Peripheral Neuropathy (DPN)

37 Americans
live with
diabetes¹
MILLION

50% Will suffer
from DPN²

The American Diabetes Association (ADA) recommends referring DPN patients to a Pain Clinic when pharmacological therapies have no meaningful effect^{3,4}



Topical
Treatment



Pharmacological
Therapies



Interventional
Pain Therapies
(Including SCS)


Due to high risk of addiction and complications, the
ADA does not recommend the use of opioids as first
or second-line agents for treating DPN patients

REAL-WORLD DPN EVIDENCE OUT TO 3 YEARS⁵

Boston Scientific's real-world RELIEF registry demonstrated high responder rates of ≥75%
and ~90% sustained improvement out to 3-years



RESPONDER RATE



SUSTAINED PATIENT
IMPROVEMENT

THE WAVEWRIter ALPHA™ SCS SYSTEM

Bringing our proven SCS technology and profound pain relief to DPN patients

- 4 IPGs | 16 and 32 contact options
- Rechargeable and non-rechargeable
- Full-body MRI access*
- Bluetooth® enabled
- All the latest therapies†



REACH OUT TO YOUR BOSTON SCIENTIFIC REPRESENTATIVE
TO LEARN MORE ABOUT EXPLORING SCS FOR YOUR DPN PATIENTS

Learn more about The WaveWriter Alpha™ SCS System



References:

1. American Diabetes Association. Statistics about diabetes. <https://diabetes.org/about-diabetes/statistics/about-diabetes> Accessed October 8, 2023.
2. Hicks, Selvin. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Current Diabetes Reports. 2019 Aug 27; 19(10): 86.
3. Pop-Busui R, Ang L, Boulton A, et al. Diagnosis and treatment of painful diabetic peripheral neuropathy. Compendia. 2022;2022(1):1-32.
4. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154.
5. Chaiban G, et al. Real-World Outcomes in Patients Using SCS for Treatment of Painful Diabetic Peripheral Neuropathy (DPN) [Abstract]. Twenty-sixth Annual Meeting of the North American Neuromodulation Society, January 13-15th, 2023. (n=58)
 - Responder Rate: (n=23 @ 1 year, n=16 @ 2 years, & n=12 @ 3 years, Ongoing study)
 - Sustained Patient Improvement: (n=24 @ 1 year, n=16 @ 2 years, & n=12 @ 3 years, Ongoing study)



*The WaveWriter Alpha™ SCS System provides safe access to full-body MRI scans when used with specific components and the patient is exposed to the MRI environment under the defined conditions in the ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha and WaveWriter Alpha Prime Spinal Cord Stimulator System.

†Stimulation modes. Only paresthesia-based stimulation mode has been evaluated for effectiveness in the diabetic peripheral neuropathy (DPN) population.

The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Boston Scientific Neuromodulation Corporation is under license.

Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.

The Boston Scientific Spinal Cord Stimulator Systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, Diabetic Peripheral Neuropathy of the lower extremities, intractable low back pain and leg pain. Associated conditions and etiologies may be: radicular pain syndrome, radiculopathies resulting in pain secondary to failed back syndrome or herniated disc, law restricts this device to sale by or on the order of a physician. epidural fibrosis, degenerative disc disease (herniated disc pain refractory to conservative and surgical interventions), arachnoiditis, multiple back surgeries. Contraindications, warnings, precautions, side effects. The SCS Systems are contraindicated for patients who: are unable to operate the SCS System, have failed trial stimulation by failing to receive effective pain relief, are poor surgical candidates, or are pregnant. Warning: Stimulation modes. Only paresthesia-based stimulation mode has been evaluated for effectiveness in the Diabetic Peripheral Neuropathy (DPN) population. Refer to the Instructions for Use provided with the SCS System or Pain.com for potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

NM-1733904-AA ©2023 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are the property of their respective owners.